Last reviewed · How we verify

Januvia — Competitive Intelligence Brief

Januvia (SITAGLIPTIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dipeptidyl Peptidase 4 Inhibitor [EPC]. Area: Metabolic.

marketed Dipeptidyl Peptidase 4 Inhibitor [EPC] Dipeptidyl peptidase 4 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Januvia (SITAGLIPTIN) — Zydus Lifesciences. Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Januvia TARGET SITAGLIPTIN Zydus Lifesciences marketed Dipeptidyl Peptidase 4 Inhibitor [EPC] Dipeptidyl peptidase 4 2006-01-01
Suganon EVOGLIPTIN Dong-A ST marketed Dipeptidyl peptidase 4 2015-01-01
Nesina ALOGLIPTIN Takeda marketed Dipeptidyl Peptidase 4 Inhibitor Dipeptidyl peptidase 4 2013-01-01
Suiny ANAGLIPTIN marketed Dipeptidyl peptidase 4 2012-01-01
Tradjenta BI 1356 Boehringer Ingelheim marketed Dipeptidyl Peptidase 4 Inhibitor [EPC] Dipeptidyl peptidase 4 2011-01-01
Tradjenta LINAGLIPTIN Boehringer Ingelheim marketed Dipeptidyl Peptidase 4 Inhibitor [EPC] Dipeptidyl peptidase 4 2011-01-01
Jalra VILDAGLIPTIN marketed vildagliptin Dipeptidyl peptidase 4 2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Dipeptidyl Peptidase 4 Inhibitor [EPC] class)

  1. · 2 drugs in this class
  2. Boehringer Ingelheim · 2 drugs in this class
  3. Generic (originally Merck Serono/Lipha) · 1 drug in this class
  4. Institut für Pharmakologie und Präventive Medizin · 1 drug in this class
  5. University Medical Centre Ljubljana · 1 drug in this class
  6. Zhujiang Hospital · 1 drug in this class
  7. Zydus Lifesciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Januvia — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: